Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:05 ET
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 15, 2024 08:00 ET
|
Phathom Pharmaceuticals
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD)...
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 15, 2024 06:59 ET
|
atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 16:00 ET
|
Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 07:00 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024 06:05 ET
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.